Transgene

TNG

FR0005175080

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 16:55:00 20/05/2026 BST			5-day change	1st Jan Change
0.8350 ^EUR	0.00%		-1.76%	-13.02%

04-13	Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer	CI
04-07	Transgene stands out following licensing agreement with NEC Bio

Transgene, NEC Bio Enter Partnership to Develop Cancer Vaccine

Published on 04/03/2026 at 06:18 am BST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Transgene

04-13	Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer	CI
04-07	Transgene stands out following licensing agreement with NEC Bio
04-03	Transgene, NEC Bio Enter Partnership to Develop Cancer Vaccine	MT
04-02	Transgene and NEC Bio Sign License Agreement for TG4050 Development in Head and Neck Cancer	CI
04-02	Transgene & NEC Bio sign license agreement to prepare next steps of development of TG4050 in head & neck cancer	RE
03-25	Danone, Dassault Systèmes, Orange... stocks to watch today in Paris
03-24	Transgene SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Transgene SA, 2025 Earnings Call, Mar 24, 2026
03-24	Transgene SA says myvac platform to initiate phase 1 trial in second indication in 2026	RE
03-24	Ipsos, NRJ Group, Transgene: Stocks to watch tomorrow in Paris
03-24	Transgene reports full-year results and provides operational update
03-24	Abivax, Ekinops, Sanofi... stocks to watch today in Paris
03-02	Certain Ordinary Shares of Transgene SA are subject to a Lock-Up Agreement Ending on 2-MAR-2026.	CI
02-24	Adocia SA Announces Board Changes	CI
01-23	JCDecaux, Sanofi, Sword Group... Stocks to Watch Today in Paris

Transgene is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. Transgene has a portfolio of 4 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene has a production site in France.

Employees

145

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company